Skip to main content
Journal of Ophthalmic Inflammation and Infection
Fig. 2 | Journal of Ophthalmic Inflammation and Infection

Fig. 2

From: Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study

Fig. 2

Schematic representation showing clinical course and treatment regime. Duration of medication (open bars) and patient’s symptoms (closed bars) showing that after initiating canakinumab therapy (arrows), all physical symptoms (rash, arthralgia, aseptic meningitis, and fever) and ophthalmic symptoms (conjunctival injection, ulcerative keratitis, anterior chamber inflammation, and hypopyon) were resolved within a few days. In addition, the level of C-reactive protein (CRP) normalized and stabilized. No recurrence or adverse events were observed during a follow-up period of 18 months

Back to article page